Biotech Values

[urche]

What are the naysayers saying?

This has probably been addressed on the
BTV board, which I admit to being unable to keep up with.
But I am surprised at the drop in price on what appears to be a good deal for a phase 2 drug. And it was not really expected as far as I know, so the sell on the news investors shouldn't have built this into their strategy.

I would be interested in what the market sees as disappointing enough in this deal to send IDIX down on an up day for the market?

Urche
(cross posted on IDIX board which seems underutilized)